Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study.

This study looked at how XTANDI (enzalutamide), in combination with leuprolide and as a monotherapy, works for men who have a type of prostate cancer called non-metastatic hormone-sensitive prostate cancer (nmHSPC), which is also known as nonmetastatic castration-sensitive prostate cancer or (nmCSPC). The men who were a part of the study had a return of signs of cancer, called biochemical recurrence (BCR), and were at high risk for metastasis.

Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

For patients who took XTANDI plus leuprolide, the study showed a clear and important improvement in overall survival compared to those who were treated with placebo plus leuprolide.

The study showed that using XTANDI can help extend life for men with nmHSPC and high-risk BCR.

Currently, XTANDI is approved in over 80 countries, including the US, the European Union, and Japan.

Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotechnology corporation that is known for discovering, developing, and manufacturing healthcare products, including innovative medicines and vaccines.

While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.